سعر ستيلارا 90مجم/مل سرنجة معبأة للحقن تحت الجلد 2024

STELARA (ustekinumab 90 mg/1 mL per prefilled syringe, Janssen-Cilag, Egypt): human monoclonal antibody against the IL-12/IL-23 p40 subunit, used in psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.

• Moderate to severe plaque psoriasis in adults and children 6 years and older who are candidates for phototherapy or systemic therapyPopulation: Adults and children 6 years and olderDailyMed (U.S. National Library of Medicine)
• Active psoriatic arthritis in adults and children 6 years and olderPopulation: Adults and children 6 years and olderDailyMed (U.S. National Library of Medicine)
• Moderately to severely active Crohn's disease in adults and children 2 years and olderPopulation: Adults and children 2 years and olderDailyMed (U.S. National Library of Medicine)

• Psoriasis and psoriatic arthritis (3% or more): nasopharyngitis, upper respiratory tract infection, headache, fatigue.International label, same product · DailyMed (U.S. National Library of Medicine)
• Crohn's disease: induction - vomiting; maintenance - nasopharyngitis, injection site erythema, vulvovaginal candidiasis, bronchitis, pruritus, urinary tract infection, sinusitis.International label, same product · DailyMed (U.S. National Library of Medicine)
• Ulcerative colitis: induction - nasopharyngitis; maintenance - nasopharyngitis, headache, abdominal pain, influenza, fever, diarrhoea, sinusitis, fatigue, nausea.International label, same product · DailyMed (U.S. National Library of Medicine)

• Clinically significant hypersensitivity to any ustekinumab product or to any excipient.International label, same product · DailyMed (U.S. National Library of Medicine)

• May increase the risk of infections and reactivation of latent infections; serious bacterial, mycobacterial, fungal and viral infections observed. Do not start during clinically important active infection.International label, same product · DailyMed (U.S. National Library of Medicine)
• Evaluate for tuberculosis before starting; avoid in active TB and treat latent TB before initiation.International label, same product · DailyMed (U.S. National Library of Medicine)
• Immunosuppressant that may increase the risk of malignancy; monitor for non-melanoma skin cancer, especially in patients over 60, with prolonged immunosuppression or prior PUVA.International label, same product · DailyMed (U.S. National Library of Medicine)

• Live vaccines (including BCG)Avoid live vaccines during treatment; avoid BCG during treatment and for one year before or after.DailyMed (U.S. National Library of Medicine)

• Pregnancy registry (OTIS/MotherToBaby), published literature and pharmacovigilance data have not identified a STELARA-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes; untreated inflammatory bowel disease carries risks for mother and fetus.International label, same product · DailyMed (U.S. National Library of Medicine)
• Limited published data suggest ustekinumab is present in human milk; effects of the limited exposure in the breastfed infant are unknown, and no causally related adverse effects in breastfed infants have been identified.International label, same product · DailyMed (U.S. National Library of Medicine)

• Ustekinumab: Binds the shared p40 subunit of IL-12 and IL-23, preventing their interaction with the IL-12Rbeta1 receptor and disrupting IL-12/IL-23 mediated signalling and cytokine cascades.